{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010182","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.041056+00:00","generated_at":"2026-05-17T20:54:24.867067+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harmony Biosciences Q2 revenue $200.5M (+16% YoY); EPS $0.68; reaffirms FY guidance $820-860M","bullets":["Net product revenue $200.5M (+16% YoY); GAAP net income $39.8M ($0.68 diluted EPS); non-GAAP adj. net income $53.8M ($0.92 diluted EPS).","Reaffirms 2025 revenue guidance $820M-$860M; added 400 average patients to 7,600 in Q2.","Phase 3 ZYN002 topline data in Fragile X syndrome on track for Q3 2025; targets ~80K U.S. patients.","Entered research collaboration with CiRC Biosciences for refractory epilepsy & narcolepsy; $15M upfront paid.","Settled ANDA litigation with Lupin; generic launch no earlier than Jan 2030 (or July 2030 with pediatric exclusivity)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010182","json":"https://secwatch.observer/filing/0001558370-25-010182.json","markdown":"https://secwatch.observer/filing/0001558370-25-010182.md","text":"https://secwatch.observer/filing/0001558370-25-010182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/0001558370-25-010182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:54:24.867067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}